市場調查報告書
商品編碼
1410911
全球沙眼衣原體/淋病檢測市場 - 市場規模(按細分市場)、份額、監管、報銷、預測(~2033)Chlamydia Trachomatis and Neisseria Gonorrhoeae Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
本報告研究和分析了全球沙眼衣原體/淋病檢測市場,並提供了有關每個細分市場的市場規模、市場趨勢、競爭格局以及 COVID-19 影響的資訊。
市場模型的主要內容如下。
已上市的沙眼衣原體/淋球菌檢測和不斷變化的競爭格局
全球、區域和國家層面的特定市場考量
透過對醫療保健系統的真正整體了解來加速市場了解。市場進入部分還提供有關報銷政策和監管環境的信息,使您能夠更深入地研究市場動態。
目標公司
Chlamydia Trachomatis and Neisseria Gonorrhoeae Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.
The model discusses in detail the impact of COVID-19 on Chlamydia Trachomatis and Neisseria Gonorrhoeae Tests market for the year 2020 and beyond. Chlamydia Trachomatis and Neisseria Gonorrhoeae can be transmitted during anal, oral, or vaginal sex. It can also be passed from a mother to her newborn child during childbirth. The disease is more common in women and young adults (15-24 years). In general, the number of Artificial Insemination (AI), or Intrauterine Insemination (IUI), procedures performed globally is growing due to increases in the number of men and women suffering from infertility caused by Chlamydia Trachomatis and Neisseria Gonorrhoeae infection.
Chlamydia Trachomatis and Neisseria Gonorrhoeae Tests model includes Chlamydia Trachomatis Nucleic Acid Amplification Tests (NAATs) and other Chlamydia Trachomatis tests (include Direct Fluorescent Antibody (DFA), Indirect Fluorescent Antibody (IFA), Immunochromatography, Enzyme Linked Immuno Sorbent Assay (ELISA)) as sub-segments.
Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.
Key Inclusions of the market model are:
Currently marketed Chlamydia Trachomatis and Neisseria Gonorrhoeae Tests and evolving competitive landscape:
Global, Regional and Country level market specific insights:
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered: F. Hoffmann-La Roche Ltd, Abbott Laboratories, Thermo Fisher Scientific Inc , Danaher Corp, Becton Dickinson and Co ,Hologic Inc, Quidelortho Corp, Bio-Rad Laboratories Inc, Trinity Biotech Plc, ZeptoMetrix Corporation, and others.
Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile
This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -
The model will enable you to -
Not Applicable
Not Applicable
Not Applicable